Login to Your Account

Washington Roundup

Hydrocodone Combo Products Come Under FDA Microscope

By Marie Powers
Staff Writer

Monday, October 29, 2012

In a two-day meeting that begins this morning, the FDA's Drug Safety and Risk Management (DSaRM) Advisory Committee (adcom) will examine the potential impact of rescheduling hydrocodone combination products – those mixed with other analgesics or as an antitussive – from Schedule III to II, similar to hydrocodone alone.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription